p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study

Author： Kai Kazuharu   Nishimura Reiki   Arima Nobuyuki   Miyayama Haruhiko   Iwase Hirotaka  

Publisher： Springer Publishing Company

ISSN： 1341-9625

Source： International Journal of Clinical Oncology, Vol.11, Iss.6, 2006-12, pp. : 426-433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Organochlorines, p53 mutations in relation to breast cancer risk and survival. A Danish cohort-nested case-controls study

By Høyer A.P.  

Breast Cancer Research and Treatment, Vol. 71, Iss. 1, 2002-01 ,pp. : 59-65

Springer Publishing Company

Access to resources Recommend Favorite

p53 as a Marker of Prognosis in African-American Women with Breast Cancer

By Dookeran Keith  

Annals of Surgical Oncology, Vol. 17, Iss. 5, 2010-05 ,pp. : 1398-1405

Springer Publishing Company

Access to resources Recommend Favorite

Invariant p53 immunostaining in primary and recurrent breast cancer

By Poelman S.M.   Heimann R.   Fleming G.F.   Recant W.M.   Conzen S.D.  

European Journal of Cancer, Vol. 40, Iss. 1, 2004-01 ,pp. : 28-32

Elsevier

Access to resources Recommend Favorite

Death due to liver failure during endocrine therapy for premenopausal breast cancer

By Rabaglio Manuela   Ruepp Barbara    

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 874-876

Informa Healthcare

Access to resources Recommend Favorite

Application status of tamoxifen in endocrine therapy for early breast cancer

By            

Experimental and Therapeutic Medicine, Vol. 9, Iss. 6, 2015-01 ,pp. : 2207-2212

Spandidos Publications

Access to resources Recommend Favorite